Relistor

Wyeth has launched Relistor (methylnaltrexone bromide) for the treatment of opioid-induced constipation.

Relistor
Relistor

PHARMACOLOGY
Methylnaltrexone bromide is a selective, peripherally acting antagonist of opioid binding at the mu-opioid receptor.

As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted, allowing methylnaltrexone to function in tissues such as the gastrointestinal tract, without impacting opioid-mediated analgesic effects in the central nervous system.

CLINICAL STUDIES
In one study1, 154 patients were randomised to receive a single dose of methylnaltrexone or placebo. Rescue-free laxation* within 4 hours occurred in 62% and 58% in the methylnaltrexone 0.15mg/kg and 0.30mg/kg groups, respectively. In the placebo group, 14% of patients had rescue-free laxation within 4 hours (p<0.0001).

In another study2 133 patients were randomised to receive methylnaltrexone 0.15mg/kg or placebo every other day for 2 weeks. In the methylnaltrexone group, 48% of patients had laxation within 4 hours after the first study dose, as compared with 15% in the placebo group.

* A bowel movement without the use of additional laxatives

View Relistor drug record

REFERENCES
1. Poster presentation: Wellman C, Wilson, G, Israel, R. Methylnaltrexone in the treatment of opioid-induced constipation in patients with advanced illness: Results of two phase 3 trials.
2. Thomas J, Karver S, Cooney G et al. Methylnaltrexone for opioid-induced constipation in advanced illness. NEJM 2008: 358; 2332-43.


Further information: Wyeth

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in